Levetiracetam Actavis Group (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilising neuronal firing and decreasing excitability, it limits the spread of abnormal electrical activity that underlies seizures, without directly influencing ion channels or GABA receptors.

The dosage of levetiracetam is individualized and set by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals determine the appropriate starting dose and titration schedule to achieve optimal seizure control.

Levetiracetam is classified as pregnancy category B, indicating no evidence of risk in animal studies and limited human data. It may be used when the potential benefit justifies the potential risk. Limited data suggest it is excreted in breast milk, so breastfeeding decisions should be made with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Levetiracetam offers a favorable safety profile and minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. Its unique SV2A mechanism provides effective seizure control with fewer metabolic concerns, though individual response varies and clinicians choose therapy based on patient‑specific factors.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed to maintain product stability.

Levetiracetam Actavis Group is administered orally, usually as whole tablets swallowed with water. The exact dosing schedule—once daily, twice daily, or more frequent—depends on the prescriber’s instructions and the patient’s therapeutic needs.

Serious risks include severe allergic reactions (e.g., rash, swelling, breathing difficulty), mood disorders such as depression or suicidal thoughts, and rare hematologic or hepatic abnormalities. Patients should be monitored for these events, and any concerning symptoms should prompt immediate medical evaluation.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications that may reduce its effectiveness.